GlassScriptPhysician profile
Haley Flanders
NPI 1578105771
$1,396.39
in general payments reported to CMS, 2019-2025
31 companies · $901 in 2025
The $901 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.97 · 2024: $413 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $199.85 | 2024-2025 | Imfinzi, Imjudo, Enhertu |
| Regeneron Healthcare Solutions, INC. | $178.61 | 2024-2025 | Libtayo |
| Genmab U.S., INC. | $101.13 | 2024-2025 | Epkinly, Tivdak |
| Janssen Biotech, INC. | $97.86 | 2024-2025 | Tecvayli |
| Merck Sharp & Dohme LLC | $77.63 | 2024-2025 | Welireg, Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $77.22 | 2024-2025 | |
| Glaxosmithkline, LLC. | $56.90 | 2025 | Zejula, Jemperli |
| Daiichi Sankyo INC. | $48.29 | 2025 | Vanflyta |
| Adc Therapeutics America, INC. | $43.33 | 2024-2025 | |
| Pfizer INC. | $37.90 | 2025 | |
| Caris Mpi, INC. | $34.88 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $34.27 | 2024 | Orserdu, Elzonris |
| Springworks Therapeutics, INC. | $32.43 | 2025 | Gomekli, Ogsiveo |
| Pacira Pharmaceuticals Incorporated | $32.07 | 2021 | |
| Tempus Ai, INC | $28.40 | 2025 | Xt Cdx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $27.68 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.06 | 2025 | Iclusig |
| Avanos Medical | $24.70 | 2025 | Pnb and Accessories |
| Geron Corporation | $23.00 | 2025 | Rytelo |
| Heron Therapeutics, INC. | $22.30 | 2021 | |
| Exelixis INC. | $21.92 | 2025 | Cabometyx |
| Emd Serono, INC. | $20.67 | 2024 | |
| Taiho Oncology, INC. | $18.91 | 2025 | |
| Sobi, INC | $18.70 | 2024 | |
| Astellas Pharma US INC | $18.67 | 2025 | Veozah |
| Acrotech Biopharma INC. | $17.17 | 2025 | Beleodaq |
| Abbvie INC. | $17.16 | 2025 | |
| Blueprint Medicines Corporation | $16.80 | 2024 | Ayvakit |
| Lilly USA, LLC | $14.28 | 2025 | Verzenio, Jaypirca, Retevmo |
| Integra Lifesciences Corporation | $14.13 | 2021 | |
| Kci USA, INC. | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Flanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.